InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,463.14
(
0.41%
)
Post# of 647234
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Covid19freak

Send PM Follow Ignore
Followers 10
Posts 1249
Boards Moderated 0
Alias Born 07/20/2020

Covid19freak

Re: None

Wednesday, 02/07/2024 9:36:34 AM

Wednesday, February 07, 2024 9:36:34 AM

Post# of 647234
NRXP $0.38 - Phase 2/3 results imminent should come by end of this month or ealry march .. market cap only $33 million

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://www.finanznachrichten.de/nachrichten-2024-01/61194548-nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-completion-of-enrollment-of-its-phase-2b-3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-008.htm

Exceeded originally target enrollment (70) with n=74
Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter
Positive data triggers milestone payment from Alvogen, as previously announced.

company presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up